Research ExplorerPublicationsA nuclear shift of GSK3β protein is an independent prognosti...

A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer

Standard

A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer. / Eichenauer, Till; Hussein, Mohammad; Hube-Magg, Claudia; Kluth, Martina; Büscheck, Franziska; Höflmayer, Doris; Tsourlakis, Maria Christina; Steurer, Stefan; Clauditz, Till S; Luebke, Andreas M; Burandt, Eike; Wilczak, Waldemar; Hinsch, Andrea; Dum, David; Beyer, Burkhard; Steuber, Thomas; Huland, Hartwig; Graefen, Markus; Simon, Ronald; Sauter, Guido; Melling, Nathaniel; Schlomm, Thorsten; Minner, Sarah.

In: ONCOTARGET, Vol. 10, No. 18, 01.03.2019, p. 1729-1744.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Eichenauer, T, Hussein, M, Hube-Magg, C, Kluth, M, Büscheck, F, Höflmayer, D, Tsourlakis, MC, Steurer, S, Clauditz, TS, Luebke, AM, Burandt, E, Wilczak, W, Hinsch, A, Dum, D, Beyer, B, Steuber, T, Huland, H, Graefen, M, Simon, R, Sauter, G, Melling, N, Schlomm, T & Minner, S 2019, 'A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer', ONCOTARGET, vol. 10, no. 18, pp. 1729-1744. https://doi.org/10.18632/oncotarget.26739

APA

Eichenauer, T., Hussein, M., Hube-Magg, C., Kluth, M., Büscheck, F., Höflmayer, D., Tsourlakis, M. C., Steurer, S., Clauditz, T. S., Luebke, A. M., Burandt, E., Wilczak, W., Hinsch, A., Dum, D., Beyer, B., Steuber, T., Huland, H., Graefen, M., Simon, R., ... Minner, S. (2019). A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer. ONCOTARGET, 10(18), 1729-1744. https://doi.org/10.18632/oncotarget.26739

Vancouver

Eichenauer T, Hussein M, Hube-Magg C, Kluth M, Büscheck F, Höflmayer D et al. A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer. ONCOTARGET. 2019 Mar 1;10(18):1729-1744. https://doi.org/10.18632/oncotarget.26739

Bibtex

@article{c307778518ff45c29b5e44e427aa3305,
title = "A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer",
abstract = "Glycogen synthase kinase 3{\ss} (GSK3{\ss}) regulates many cancer relevant cellular processes and represents a potential therapeutic target. GSK3{\ss} overexpression has been linked to adverse tumor features in many cancers, but its role in prostate cancer remains uncertain. We employed immunohistochemical GSK3{\ss} expression analysis on a tissue microarray with 12,427 prostate cancers. Cytoplasmic and nuclear GSK3{\ss} staining was separately analyzed. GSK3{\ss} staining was absent in normal prostate epithelium, whereas 57% of 9,164 interpretable cancers showed detectable GSK3{\ss} expression. Cytoplasmic staining was considered weak, moderate, and strong in 36%, 19.5% and 1.5% of tumors and was accompanied by nuclear GSK3{\ss} staining in 47% of cases. Cytoplasmic GSK3{\ss} staining as well as nuclear GSK3{\ss} accumulation was associated with advanced tumor stage, high Gleason grade, presence of lymph node metastasis and early biochemical recurrence (p < 0.0001 each for cytoplasmic staining and nu-clear accumulation). Prognosis of GSK3{\ss} positive cancers became particularly poor if nuclear GSK3{\ss} staining was also seen (p < 0.0001). The prognostic impact of nuclear GSK3{\ss} accumu-lation was independent of established preoperative and postoperative parameters in multivari-ate analyses (p < 0.0001). The significant association of GSK3{\ss} expression with deletions of PTEN, 3p13 (p < 0.0001 each), 5q21 (p = 0.0014) and 6q15 (p = 0.0026) suggest a role of GSK3{\ss} in the development of genomic instability. In summary, the results of our study identify GSK3{\ss} as an independent prognostic marker in prostate cancer.",
author = "Till Eichenauer and Mohammad Hussein and Claudia Hube-Magg and Martina Kluth and Franziska B{\"u}scheck and Doris H{\"o}flmayer and Tsourlakis, {Maria Christina} and Stefan Steurer and Clauditz, {Till S} and Luebke, {Andreas M} and Eike Burandt and Waldemar Wilczak and Andrea Hinsch and David Dum and Burkhard Beyer and Thomas Steuber and Hartwig Huland and Markus Graefen and Ronald Simon and Guido Sauter and Nathaniel Melling and Thorsten Schlomm and Sarah Minner",
year = "2019",
month = mar,
day = "1",
doi = "10.18632/oncotarget.26739",
language = "English",
volume = "10",
pages = "1729--1744",
journal = "ONCOTARGET",
issn = "1949-2553",
publisher = "IMPACT JOURNALS LLC",
number = "18",

}

RIS

TY - JOUR

T1 - A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer

AU - Eichenauer, Till

AU - Hussein, Mohammad

AU - Hube-Magg, Claudia

AU - Kluth, Martina

AU - Büscheck, Franziska

AU - Höflmayer, Doris

AU - Tsourlakis, Maria Christina

AU - Steurer, Stefan

AU - Clauditz, Till S

AU - Luebke, Andreas M

AU - Burandt, Eike

AU - Wilczak, Waldemar

AU - Hinsch, Andrea

AU - Dum, David

AU - Beyer, Burkhard

AU - Steuber, Thomas

AU - Huland, Hartwig

AU - Graefen, Markus

AU - Simon, Ronald

AU - Sauter, Guido

AU - Melling, Nathaniel

AU - Schlomm, Thorsten

AU - Minner, Sarah

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Glycogen synthase kinase 3ß (GSK3ß) regulates many cancer relevant cellular processes and represents a potential therapeutic target. GSK3ß overexpression has been linked to adverse tumor features in many cancers, but its role in prostate cancer remains uncertain. We employed immunohistochemical GSK3ß expression analysis on a tissue microarray with 12,427 prostate cancers. Cytoplasmic and nuclear GSK3ß staining was separately analyzed. GSK3ß staining was absent in normal prostate epithelium, whereas 57% of 9,164 interpretable cancers showed detectable GSK3ß expression. Cytoplasmic staining was considered weak, moderate, and strong in 36%, 19.5% and 1.5% of tumors and was accompanied by nuclear GSK3ß staining in 47% of cases. Cytoplasmic GSK3ß staining as well as nuclear GSK3ß accumulation was associated with advanced tumor stage, high Gleason grade, presence of lymph node metastasis and early biochemical recurrence (p < 0.0001 each for cytoplasmic staining and nu-clear accumulation). Prognosis of GSK3ß positive cancers became particularly poor if nuclear GSK3ß staining was also seen (p < 0.0001). The prognostic impact of nuclear GSK3ß accumu-lation was independent of established preoperative and postoperative parameters in multivari-ate analyses (p < 0.0001). The significant association of GSK3ß expression with deletions of PTEN, 3p13 (p < 0.0001 each), 5q21 (p = 0.0014) and 6q15 (p = 0.0026) suggest a role of GSK3ß in the development of genomic instability. In summary, the results of our study identify GSK3ß as an independent prognostic marker in prostate cancer.

AB - Glycogen synthase kinase 3ß (GSK3ß) regulates many cancer relevant cellular processes and represents a potential therapeutic target. GSK3ß overexpression has been linked to adverse tumor features in many cancers, but its role in prostate cancer remains uncertain. We employed immunohistochemical GSK3ß expression analysis on a tissue microarray with 12,427 prostate cancers. Cytoplasmic and nuclear GSK3ß staining was separately analyzed. GSK3ß staining was absent in normal prostate epithelium, whereas 57% of 9,164 interpretable cancers showed detectable GSK3ß expression. Cytoplasmic staining was considered weak, moderate, and strong in 36%, 19.5% and 1.5% of tumors and was accompanied by nuclear GSK3ß staining in 47% of cases. Cytoplasmic GSK3ß staining as well as nuclear GSK3ß accumulation was associated with advanced tumor stage, high Gleason grade, presence of lymph node metastasis and early biochemical recurrence (p < 0.0001 each for cytoplasmic staining and nu-clear accumulation). Prognosis of GSK3ß positive cancers became particularly poor if nuclear GSK3ß staining was also seen (p < 0.0001). The prognostic impact of nuclear GSK3ß accumu-lation was independent of established preoperative and postoperative parameters in multivari-ate analyses (p < 0.0001). The significant association of GSK3ß expression with deletions of PTEN, 3p13 (p < 0.0001 each), 5q21 (p = 0.0014) and 6q15 (p = 0.0026) suggest a role of GSK3ß in the development of genomic instability. In summary, the results of our study identify GSK3ß as an independent prognostic marker in prostate cancer.

U2 - 10.18632/oncotarget.26739

DO - 10.18632/oncotarget.26739

M3 - SCORING: Journal article

C2 - 30899444

VL - 10

SP - 1729

EP - 1744

JO - ONCOTARGET

JF - ONCOTARGET

SN - 1949-2553

IS - 18

ER -